Home > Healthcare > Pharmaceuticals > Vaccines > Rabies Vaccine Market

Rabies Vaccine Market Share

Report ID: GMI9865
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Rabies Vaccine Market Share

The market is characterized by a highly competitive landscape with several key players vying for market share. Companies such as Sanofi, GlaxoSmithKline, and Merck & Co. are among the prominent players in the market, offering a range of rabies vaccines for both human and animal use. These companies focus on research and development to enhance the efficacy and safety profiles of their vaccines, as well as on expanding their geographical presence through strategic partnerships and collaborations.

Additionally, the market is witnessing the entry of new players, especially in emerging economies, which is intensifying competition. Factors such as increasing awareness about rabies prevention, government initiatives for vaccination programs, and rising incidences of rabies cases globally are driving the growth of the market, further fuelling competition among key players.

Rabies Vaccine Market Companies

Prominent players operating in the rabies vaccine industry include:

Bavarian Nordic A/S
Bharat Biotech International Limited
Bio-Manguinhos/Fiocruz
Cadila Pharmaceuticals
China National Biotec Group Co.
Elanco Animal Health Incorporated
GSK plc.
Indian Immunologicals Ltd.
Liaoning Chengda Biological
Merck & Co., Inc.
Novartis AG
Sanofi SA
Serum Institute of India Pvt. Ltd
Virbac
Zoetis Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global rabies vaccine industry was valued at USD 1.1 billion in 2023 and is anticipated to register 4.5% CAGR between 2024 and 2032, driven by increasing incidence of rabies and technological advancements in vaccine production.

The human segment in the market is expected to reach USD 418.51 million by 2032 due to the increasing incidence of rabies and heightened awareness about the fatal consequences of rabies.

North America rabies vaccine market is expected to reach USD 635.7 million by 2032 due to the region's robust healthcare infrastructure and high awareness of rabies prevention.

Bavarian Nordic A/S, Bharat Biotech International Limited, Bio-Manguinhos/Fiocruz, Cadila Pharmaceuticals, China National Biotec Group Co., Elanco Animal Health Incorporated, GSK plc., and Indian Immunologicals Ltd., among others.